Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 New Entrants companies in PCSK9 Inhibitors
by Most Patent Filing In 3 Years in the world in 2021

The PCSK9 Inhibitors top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filing In 3 Years PCSK9 Inhibitors New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2021, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
#
Company Name
Region
Tech Topics
Total
1
Cambridgeshire, United Kingdom
Patent: 19
2
Cambridgeshire, United Kingdom
Medicine,Health care,Side effect,
...[+2]
Patent: 19
3
Basel-Stadt, Switzerland
Dosage form,Health care,Medicine,
...[+2]
Patent: 16
4
Massachusetts, United States
Health care,Mitral valve surgery,Health equity,
...[+2]
Patent: 5
5
North Carolina, United States
Patent: 4
6
Dogma Therapeutics, Inc.
Massachusetts, United States
PCSK9,Cardiovascular agent,Biophysics,
...[+2]
Patent: 3
7
Île-de-France, France
Patent: 3
8
Massachusetts, United States
Medicine,Health care,Drug class,
...[+2]
Patent: 3
9
Patent: 3
10
Manchester, United Kingdom
Health care,Hospitality industry
Patent: 2
11
Tokyo, Japan
Patent: 2
12
South Korea
Patent: 2
13
Patent: 2
14
Patent: 2
15
Daegu, South Korea
Asset management,Impact investing,Social Welfare
Patent: 2
16
LORRAINE, France
Patent: 1
17
Patent: 1
18
CN
Patent: 1
19
Patent: 1
20
Chemistry,Mathematics,Inorganic chemistry,
...[+2]
Patent: 1
Page generation time: May 17 2025